<DOC>
	<DOCNO>NCT01753323</DOCNO>
	<brief_summary>This study ass efficacy , safety , tolerability PK uncomplicated adult malaria patient P. vivax P. falciparum infection 3 day dose KAF156 400 mg/day ( Part 1 ) single dose KAF156 800mg ( Part 2 )</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Pharmacokinetics KAF156 Adult Patients With Acute , Uncomplicated Plasmodium Falciparum Vivax Malaria Mono-infection</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<criteria>Male female patient age 20 60 year ; Presence monoinfection P. falciparum P. vivax ; Weight 40 kg 90 kg . Patients sign symptom severe/complicated malaria Infection one parasite specie Women childbearing potential ; pregnant nursing woman Those take antimalarial treatment precede 14 day investigational drug within 30 day 5 halflives</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>acute malaria , KAF156</keyword>
</DOC>